Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
暂无分享,去创建一个
H. Goldschmidt | G. Morgan | H. Einsele | J. San Miguel | P. Sonneveld | D. Auclair | N. Bolli | J. Keats | S. Lonial | N. Munshi | M. Trotter | K. Mavrommatis | M. Samur | P. Moreau | M. Fulciniti | H. Avet-Loiseau | B. Walker | F. Davies | A. Stewart | Hongwei Wang | G. Jackson | B. Durie | C. Wardell | J. Obenauer | A. Hoering | M. Raab | F. Towfic | P. Qu | Zhinuan Yu | A. Thakurta | R. Szalat | Zhihong Yang | M. Bauer | A. Stewart | Daniel K. Rozelle | K. Anderson | María Ortiz | E. Flynt | A. Rosenthal | T. C. Ashby | K. Anderson | M. Ortiz | A. Stewart | B. Walker | G. Jackson
[1] Pingping Qu,et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis , 2018, Leukemia.
[2] Chuang Tan,et al. Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.
[3] James X. Sun,et al. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? , 2018, Leukemia.
[4] D. Nowis,et al. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma , 2017, Nature Communications.
[5] N. Schultz,et al. Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. , 2017, Cancer cell.
[6] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[7] Caleb K. Stein,et al. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma , 2017, Oncotarget.
[8] J. Qiu,et al. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced , 2017, PloS one.
[9] Gabriela Alexe,et al. Characterizing genomic alterations in cancer by complementary functional associations , 2016, Nature Biotechnology.
[10] R. S. Shmookler Reis,et al. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition , 2015, Molecular Cancer Therapeutics.
[11] K. Dutton-Regester,et al. Recurrent inactivating RASA2 mutations in melanoma , 2015, Nature Genetics.
[12] A. Labno,et al. DIS3 shapes the RNA polymerase II transcriptome in humans by degrading a variety of unwanted transcripts , 2015, Genome research.
[13] Gordon Cook,et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Kathleen Marchal,et al. SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering , 2015, BMC Bioinformatics.
[15] Gordon Cook,et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.
[16] J. Cleveland,et al. Tipping the MYC–MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively blocks MYC-activated genes , 2014, EMBO molecular medicine.
[17] B. Leggett,et al. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype , 2014, Epigenetics.
[18] N. Potter,et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma , 2014, Leukemia.
[19] Chris Sander,et al. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy , 2014, The Journal of experimental medicine.
[20] C. Rudin,et al. MYC, MAX, and small cell lung cancer. , 2014, Cancer discovery.
[21] G. Morgan,et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.
[22] J. Keats,et al. Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma , 2014, Leukemia.
[23] G. Parmigiani,et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.
[24] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[25] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[26] Lisa J. Murray,et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms , 2013, Leukemia.
[27] M. Shen. Chromoplexy: a new category of complex rearrangements in the cancer genome. , 2013, Cancer cell.
[28] Richard A. Moore,et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. , 2013, Blood.
[29] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[30] D. Schadendorf,et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.
[31] A. Ashworth,et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. , 2012, Blood.
[32] G. Morgan,et al. The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.
[33] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[34] N. Munshi,et al. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. , 2011, Blood.
[35] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[36] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[37] David N. Boone,et al. Egr1 mediates p53-independent c-Myc–induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism , 2010, Proceedings of the National Academy of Sciences.
[38] S. Lonial,et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. , 2010, Blood.
[39] G. Morgan,et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.
[40] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[41] L. Staudt,et al. IRF4 addiction in multiple myeloma , 2008, Nature.
[42] L. Bruhn,et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.
[43] A. Baldwin,et al. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression , 2006, Oncogene.
[44] J. Keats,et al. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma , 2006, Leukemia & lymphoma.
[45] Bart Barlogie,et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.
[46] Mathew J Garnett,et al. Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.
[47] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[48] M. Loh,et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.
[49] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[50] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[51] J. Dudley,et al. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma , 2018, Leukemia.
[52] Trevor J Pugh,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .